Data from an ongoing phase 1/2 clinical trial evaluate three dose levels of Pfizer (NYSE: PFE) and partner BioNTech SEs (NASDAQ: BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-dependent increases in glycoprotein receptor-binding domain (RBD) -binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. The data, just published in the journal Nature, was generated at the first two dose levels, 10 eng and 30 .g. The highest dose of 100 μg was administered only once due to increased reactogenicity and the lack of a significant incremental immunogenicity effect compared to the 30 μg dose.
1.6-fold to 4.6-fold increases in geometric mean neutralizing antibody titers after the second dose were observed.
The companies first reported preliminary data from the trial on July 1st. The highest neutralizing titers then reported were 1.8x (10 )g) and 2.8x (30 .g).
Premarket: PFE up a fraction, BNTX up 4%.
